The Scottish Medicines Consortium (SMC) has approved the use of carfilzomib (Kyprolis®) in combination with dexamethasone for myeloma patients who have received at least one previous treatment. The approval is based on results from the ENDEAVOR trial which showed that progression-free survival was significantly improved in patients treated with carfilzomib in combination with dexamethasone compared to treatment with bortezomib (Velcade®) and dexamethasone.
Last month, the National Institute for Health and Care Excellence (NICE) approved carfilzomib in combination with dexamethasone for restricted use in myeloma patients who have not previously received bortezomib (Velcade®).The advice issued by the SMC does not include this restriction.